Study of Pembrolizumab and M032 (NSC 733972)

Abroad (travel likely)RecruitingPHASE1, PHASE2

Conditions

Glioblastoma Multiforme · Anaplastic Astrocytoma · Gliosarcoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

University of Alabama at Birmingham, Birmingham, Alabama, United States
Contact: Study coordinator (James Markert, MD) · jmarkert@uabmc.edu

Study leads

James Markert, MD
Principal Investigator
The University of Alabama at Birmingham

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA

Glioblastoma · Anaplastic Astrocytoma · Anaplastic Oligoastrocytoma

Abroad (travel likely)RecruitingPHASE2

New York, United States

ERAS-801 for the Treatment of Resectable and Progressive or Recurrent or Elderly Newly Diagnosed IDH Wildtype Grade IV Glioblastoma or Gliosarcoma With an EGFR Amplification or Mutation, ERAS801-SARG Trial

Glioblastoma · Glioblastoma, IDH-Wildtype · Gliosarcoma

Abroad (travel likely)RecruitingPHASE1

Los Angeles, United States · New York, United States

Study of ABBV-637 or ABBV-155 With ERAS-801 for People With Glioblastoma

Glioblastoma · Gliosarcoma

Abroad (travel likely)RecruitingPHASE1

Los Angeles, United States · Miami, United States

First-in Cancer-Type Phase I Study of FT536 for Recurrent WHO Grade 4 Astrocytoma

Astrocytoma · Glioblastoma · Progressive Disease

Abroad (travel likely)RecruitingPHASE1

Minneapolis, United States